Mga Batayang Estadistika
| LEI | 549300B6OBAWAZGW2N50 |
| CIK | 1135906 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Epirus Biopharmaceuticals Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2017 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) EPIRUS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428P107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 1, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdiction of incorporation) (Comm |
|
| July 25, 2016 |
8-K 1 a16-1520118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdict |
|
| July 11, 2016 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 epir.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 2 Name of Issuer: EPIRUS Biopharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 29428P107 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF |
|
| July 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdiction of incorporation) (Comm |
|
| June 14, 2016 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdiction of incorporation) (Comm |
|
| May 10, 2016 |
EPIRUS Biopharmaceuticals 10-Q (Quarterly Report) eprsCurrentFolio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2016 |
Exhibit 99.1 EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes ? New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator sales estimated in 2020 ? Amit Munshi steps down as preside |
|
| May 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdiction of incorporation) (Commis |
|
| April 29, 2016 |
EPIRUS Biopharmaceuticals 10-K/A (Annual Report) 10-K/A 1 a16-9302110ka.htm 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio |
|
| March 29, 2016 |
As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
Exhibit 10.25 Employment Agreement between Epirus Biopharmaceuticals (Switzerland) GmbH. General-Guisan-Strasse 6, 6303 Zug "Employer" and Vincent Aurentz [address redacted] "Employee" collectively, the "Parties" and each individually, a "Party" 2 / 10 Employment Agreement Epirus Biopharmaceuticals (Switzerland) GmbH / Vince Aurentz The Parties hereby agree on the terms and conditions of the Emplo |
|
| March 29, 2016 |
EPIRUS BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED Non-Employee DIRECTOR COMPENSATION POLICY Exhibit 10.16 EPIRUS BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED Non-Employee DIRECTOR COMPENSATION POLICY Non-employee members of the board of directors (the “Board”) of EPIRUS Biopharmaceuticals, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”). The cash and equity |
|
| March 29, 2016 |
Subsidiaries of EPIRUS Biopharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of EPIRUS Biopharmaceuticals, Inc. Name of Wholly-Owned Subsidiary Jurisdiction of Organization EB Sub, Inc. Delaware Epirus Biopharmaceuticals Ltd. United Kingdom Epirus Biopharmaceuticals (Switzerland) GmbH Switzerland Epirus Brasil Tecnologia Ltda Brazil Epirus Biopharmaceuticals (Netherlands) B.V. Netherlands |
|
| March 29, 2016 |
Exhibit 10.36 Execution Copy EPIRUS BIOPHARMACEUTICALS, INC. As Vendor - and - TARO PHARMACEUTICALS INC. As Purchaser - Regarding – ZALICUS PHARMACEUTICALS LTD. SHARE PURCHASE AGREEMENT OCTOBER 1, 2015 TABLE OF CONTENTS Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Construction 10 1.3 Certain Rules of Interpretation 10 1.4 Knowledge 11 1.5 Computation of Time 11 1.6 Performance on Business Days |
|
| March 29, 2016 |
Exhibit 10.8 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Stock Options and Option Agreement <> Option Number: <> < > Plan: 2015 Effective <>, you have been granted a(n) Incentive Stock Option to buy <> shares of EPIRUS BIOPHARMACEUTICALS, INC (the Company) stock at $<> per share. The total option price of the shares granted is $<>. Sh |
|
| March 29, 2016 |
Exhibit 10.9 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Stock Options and Option Agreement <> Option Number: <> < > Plan: 2015 Effective <>, you have been granted a(n) Non-Qualified Stock Option to buy <> shares of EPIRUS BIOPHARMACEUTICALS, INC (the Company) stock at $<> per share. The total option price of the shares granted is $<> |
|
| March 29, 2016 |
Granted Under the 2015 Equity Incentive Plan of EPIRUS Biopharmaceuticals, Inc. eprs_EX_10_10 Exhibit 10.10 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Award and Award Agreement <> Award Number: <> < > Plan: 2015 Effective <>, you have been granted an award of <> restricted stock units. These units are restricted until the vest date(s) shown below, at which time you will receive shares of EPIRUS BIOPHARMACEUTICAL |
|
| March 28, 2016 |
EPIRUS Biopharmaceuticals 10-K (Annual Report) eprsCurrentFolio10K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2016 |
EPIRUS Biopharmaceuticals NT 10-K NT 10-K 1 a16-63951nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Repo |
|
| March 15, 2016 |
Exhibit 99.1 EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update Substantial Progress Made During 2015 Advancing Six Biosimilar Assets, with Global Filings Targeted Every Year from 2017 through 2022 Boston, MA ? (GlobeNewswire) ? March 15, 2016 ? EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a pure-play biosimilar company focused o |
|
| March 15, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 1, 2016 |
$30,000,000 of Shares Common Stock 424B5 1 a2227424z424b5.htm 424B5 QuickLinks - Click here to rapidly navigate through this document Filed Pursuant to Rule 424(b)(5) Registration No. 333- 205420 PROSPECTUS SUPPLEMENT (To prospectus dated July 17, 2015) $30,000,000 of Shares Common Stock This prospectus supplement and accompanying prospectus relate to the issuance and sale of up to $30,000,000 of shares of our common stock, par val |
|
| March 1, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 29, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) ( |
|
| March 1, 2016 |
Exhibit 1.1 EPIRUS BIOPHARMACEUTICALS, INC. UP TO $30,000,000 OF COMMON STOCK (par value $0.001 per share) AT-THE-MARKET SALES AGREEMENT February 29, 2016 BTIG, LLC 825 Third Avenue, 6th Floor New York, NY 10022 Ladies and Gentlemen: EPIRUS Biopharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with BTIG, LLC (?BTIG? and, together with the Compa |
|
| February 12, 2016 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / Camber Capital Management LLC Passive Investment SC 13G/A 1 camberepirus201513gv3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) EPIRUS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428P107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 12, 2016 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment SC 13G/A 1 d7034935sc13g-a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Epirus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29428P107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 12, 2016 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 12, 2016 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 9, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-2369428k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 9, 2016 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisd |
|
| February 9, 2016 |
Exhibit 99.1 EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar) ? UNIFORM(i) Study builds on prior successful Phase 1 and Phase 3 studies ? Intended to support harmonized global filing for BOW015 in 2017 ? BOW015 is a biosimilar for Remicade?, which had global sales of $8.8 billion in 2014 Boston, MA ? (GlobeNewswire) ? February 09, 2016 ? |
|
| January 28, 2016 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 epir.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: EPIRUS Biopharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 29428P107 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF |
|
| November 16, 2015 |
Exhibit 99.1 EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update Multiple Biosimilar Product Filings for Marketing Approval in 2015 and Global Filings Anticipated Each Year from 2017 through 2022 Boston, MA ? (GlobeNewswire) ? November 16, 2015 ? EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a biopharmaceutical company focused on the global developme |
|
| November 16, 2015 |
Exhibit 10.3 New Collaboration Compound Supplement to the Collaboration Agreement by and between EPIRUS SWITZERLAND GmbH and LIVZON MABPHARM INC. This New Collaboration Compound Supplement (this ?Supplement?), dated as of September 24th , 2015 (the ?Supplement Effective Date?), to the Collaboration Agreement (as defined below), by and between EPIRUS SWITZERLAND GmbH, a Swiss corporation, having it |
|
| November 16, 2015 |
Exhibit 99.1 Bioceros Holding B.V. Financial Statements and Independent Auditors? Report December 31, 2014 and Unaudited Financial Statements As of June 30, 2015 and for the Six Months Ended June 30, 2015 and 2014 Utrecht, The Netherlands (Registered office and actual place of business) 1 Index Page Independent auditor?s report 3 Consolidated financial statements Consolidated Balance Sheets 4 Cons |
|
| November 16, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) ( |
|
| November 16, 2015 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K/A 1 a15-2241138ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-351445 |
|
| November 16, 2015 |
EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar) EX-99.2 3 a15-224112ex99d2.htm EX-99.2 Exhibit 99.2 EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar) · Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lock · BOW015 remains on track for 2017 global filing · BOW015 targets large market opportunity based on $8.8 billion global sales of Remicade |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015. Or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-5117 |
|
| November 16, 2015 |
Exhibit 10.1 EXECUTION VERSION COLLABORATION AGREEMENT BY AND BETWEEN EPIRUS SWITZERLAND GMBH AND SWISS PHARMA INTERNATIONAL AG JULY 13, 2015 Portions of this Exhibit, indicated by the mark ?[***],? were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant?s application requesting confidential treatment pursuant to Rule 24b-2 of the Securiti |
|
| November 16, 2015 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 Unaudited Pro Forma Condensed Combined Financial Information at June 30, 2015 and for the six months ended June 30, 2015 and the year ended December 31, 2014. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On September 9, 2015, EPIRUS Biopharmaceuticals, Inc. (?Epirus?, ?Company?, ?we?, ?our?, or ?us?), completed the acquisition of Bioceros Holding B.V. (?Bioceros?). The |
|
| November 10, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-2241118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Juris |
|
| November 10, 2015 |
EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer Exhibit 99.1 EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer Boston, MA ? (GlobeNewswire) ? November 10, 2015 ? EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced that Vincent E. Aurentz has joined the Company a |
|
| November 10, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. POWER OF ATTORNEY Exhibit 24 EPIRUS BIOPHARMACEUTICALS, INC. POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Amit Munshi, Thomas Shea, Robert Ticktin and Marina Breed, with full power of substitution, as the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U. |
|
| October 7, 2015 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 28, 2015 |
Entry into a Material Definitive Agreement 8-K 1 a15-1998918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Juri |
|
| September 9, 2015 |
8-K 1 a15-1852028k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Juris |
|
| September 9, 2015 |
Exhibit 2.1 STOCK PURCHASE AGREEMENT REGARDING THE SALE AND TRANSFER OF ALL OUTSTANDING SHARES IN BIOCEROS HOLDING B.V. (?BIOCEROS?) BY AND AMONG EPIRUS BIOPHARMACEUTICALS, INC., (?EPIRUS?) AND DE BOER BIOTECH CONSULTANCY B.V. UNIVERSITEIT UTRECHT HOLDING B.V. MR. A. BOUT MR. P.J. SIMONS MR. L. BOON NODENS B.V. MR. R.M.P. BRANDT MR. M.T. DEN HARTOG MRS. L.M.P. COX MRS. S.Y. MAN MRS. J.A. BIA (?SEL |
|
| September 9, 2015 |
Exhibit 99.1 EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros ? Combined companies? product pipeline targets reference biologics with sales of $29 billion in 2014 ? Pipeline expanded to include biosimilars to Soliris?, STELARA? and SIMPONI? ? Capabilities enhanced to accelerate product development and optimize quality and yields Boston, MA ? (G |
|
| August 12, 2015 |
ONE EXETER PLAZA BOSTON, MASSACHUSETTS (THE “BUILDING”) SECOND AMENDMENT MAY 29, 2015 Exhibit 10.2 ONE EXETER PLAZA BOSTON, MASSACHUSETTS (THE ?BUILDING?) SECOND AMENDMENT MAY 29, 2015 LANDLORD: CPT One Exeter Plaza, LLC, a Delaware limited liability company with a principal place of business c/o AEW Capital Management, L.P., Two Seaport Lane, World Trade Center East, Boston, MA 02210 TENANT: EPIRUS Biopharmaceuticals, Inc., a Delaware corporation EXISTING PREMISES: An area on the |
|
| August 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-12149110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015. Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Comm |
|
| August 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1715318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 7, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdic |
|
| August 7, 2015 |
EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results Exhibit 99.1 EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results BOSTON?(GlobeNewswire)?August 7, 2015?EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the second quarter and six months ended June 30, 2015. |
|
| July 16, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. 699 Boylston Street, Eighth Floor Boston, Massachusetts 02116 July 16, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director RE: EPIRUS Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 1, 2015 File No. 333-205420 |
|
| July 14, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 13, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 14, 2015 |
Exhibit 99.1 EPIRUS Biopharmaceuticals and Polpharma Group Enter into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market ? Profit-sharing collaboration focused on the commercialization of EPIRUS? biosimilars pipeline in EU, Middle East, Turkey, Russia and CIS territories (?Territories?) ? EPIRUS retains comm |
|
| July 13, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D [Rule 13d-101] (Amendment No. |
|
| July 1, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN Exhibit 99.1 EPIRUS BIOPHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Award |
|
| July 1, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1. Exhibit 99.2 EPIRUS BIOPHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1. PURPOSE The purposes of this EPIRUS Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of EPIRUS Biopharmaceuticals, Inc. (the ?Company?), and its Designated Subsidiaries in acquiring a stock ownership in |
|
| July 1, 2015 |
As filed with the Securities and Exchange Commission on July 1, 2015 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on July 1, 2015 Registration Statement No. |
|
| July 1, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. Dated as of , 20 Subordinated Debt Securities EX-4.11 3 a2225170zex-411.htm EX-4.11 Exhibit 4.11 EPIRUS BIOPHARMACEUTICALS, INC. TO Trustee Indenture Dated as of , 20 Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE ONE — DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 8 SECTION 103. Form of Documents Delivered to Trustee 9 SECTION 104. Acts of H |
|
| July 1, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. Dated as of , 20 Senior Debt Securities EX-4.9 2 a2225170zex-49.htm EX-4.9 Exhibit 4.9 EPIRUS BIOPHARMACEUTICALS, INC. TO Trustee Indenture Dated as of , 20 Senior Debt Securities TABLE OF CONTENTS Page ARTICLE ONE — DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 7 SECTION 103. Form of Documents Delivered to Trustee 8 SECTION 104. Acts of Holders 8 S |
|
| July 1, 2015 |
S-8 1 a15-143913s8.htm S-8 As filed with the Securities and Exchange Commission on July 1, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3514457 (State or Other Jurisdiction of Incorp |
|
| June 9, 2015 |
EX-3.1 2 a15-136601ex3d1.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EPIRUS BIOPHARMACEUTICALS, INC. EPIRUS Biopharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation i |
|
| June 9, 2015 |
8-K 1 a15-1366018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdicti |
|
| May 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-7956110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015. Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Comm |
|
| May 13, 2015 |
SETTLEMENT AGREEMENT RLS — Epirus BOW015 Manufacturing and Supply Agreement Exhibit 10.2 SETTLEMENT AGREEMENT Under RLS ? Epirus BOW015 Manufacturing and Supply Agreement This Settlement Agreement, dated as of 22 April, 2015 (the ?Settlement Effective Date?), is by and between Epirus Switzerland GmbH, a Swiss corporation having its principal place of business at General-Guisan-Strasse 6, 6303 Zug, Switzerland (?Epirus?), and Reliance Life Sciences Pvt. Ltd. having its reg |
|
| May 12, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1113618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdicti |
|
| May 12, 2015 |
EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results Exhibit 99.1 EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results BOSTON?(GlobeNewswire)?May 12, 2015?EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the first quarter ended March 31, 2015. ?We started the year |
|
| April 24, 2015 |
EPIRUS Biopharmaceuticals DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 24, 2015 |
EPIRUS Biopharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 22, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 24, 2015 |
EPIRUS Biopharmaceuticals DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2015 |
EPIRUS Biopharmaceuticals PRE 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 31, 2015 |
Exhibit 4.5 Schedule of Warrants Date Issued Name of Warrant Holder Number of Shares* Type of Shares Exercise Price* Expiration Date 6/27/2011 Oxford Finance LLC 1,079 Common Stock $ 83.40 12/22/2017 6/27/2011 Oxford Finance LLC 999 Common Stock $ 135.00 12/22/2017 6/27/2011 Oxford Finance LLC 888 Common Stock $ 135.00 12/22/2017 12/16/2011 Oxford Finance LLC 660 Common Stock $ 68.40 12/22/2017 12 |
|
| March 31, 2015 |
Subsidiaries of EPIRUS Biopharmaceuticals, Inc. EX-21.1 7 a2223738zex-211.htm EX-21.1 Exhibit 21.1 Subsidiaries of EPIRUS Biopharmaceuticals, Inc. Name of Wholly-Owned Subsidiary Jurisdiction of Organization EB Sub, Inc. Delaware Epirus Biopharmaceuticals Ltd. United Kingdom Epirus Switzerland GmbH Switzerland Epirus Brasil Tecnologia Ltda Brazil Zalicus Pharmaceuticals Ltd. Canada |
|
| March 31, 2015 |
EX-10.5 5 a2223738zex-105.htm EX-10.5 Exhibit 10.5 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Stock Options and Option Agreement <> Option Number: <> < > Plan: 2004 Effective <>, you have been granted a(n) Non-Qualified Stock Option to buy <> shares of EPIRUS BIOPHARMACEUTICALS, INC (the Company) stock at $<> per share. The total opt |
|
| March 31, 2015 |
<<Name>> Award Number: <<Number>> <<Address>> Plan: 2004 Exhibit 10.6 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Award and Award Agreement <> Award Number: <> < > Plan: 2004 Effective <>, you have been granted an award of <> restricted stock units. These units are restricted until the vest date(s) shown below, at which time you will receive shares of EPIRUS BIOPHARMACEUTICALS, INC (the Com |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Use these links to rapidly review the document TABLE OF CONTENTS EPIRUS Biopharmaceuticals, Inc. |
|
| March 31, 2015 |
WARRANT TO PURCHASE STOCK (Subdivided Warrant: of ) Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISF |
|
| March 31, 2015 |
Exhibit 10.4 EPIRUS BIOPHARMACEUTICALS, INC ID: 04-3514457 699 Boylston St 8th Floor Boston, MA 02116 Notice of Grant of Stock Options and Option Agreement <> Option Number: <> < > Plan: 2004 Effective <>, you have been granted a(n) Incentive Stock Option to buy <> shares of EPIRUS BIOPHARMACEUTICALS, INC (the Company) stock at $<> per share. The total option price of the shares granted is $<>. Sh |
|
| March 23, 2015 |
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results Exhibit 99.1 EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results BOSTON?(GlobeNewswire)?March 23, 2015?EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014. ?In 2014, we became a |
|
| March 23, 2015 |
EPIRUS Biopharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 23, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 13, 2015 |
EPIRUS Biopharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 13, 2015 |
Exhibit 99.1 Notice of Dismissal Without Prejudice of Zalicus, Inc. Stockholder Litigation and Agreement Upon Attorneys? Fees NEW YORK, March 13, 2015 ? Notice is hereby provided to all persons who held shares of Zalicus, Inc. (?Zalicus?) at any time during the period from and including April 16, 2014 through July 15, 2014. The purpose of this notice is to inform you about developments with respec |
|
| February 10, 2015 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / 5AM VENTURES III, L.P. - SCHEDULE 13D/A Activist Investment SC 13D/A 1 v400959sc13d-a.htm SCHEDULE 13D/A CUSIP NO. 29428P107 13D Page 1 of 13 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* EPIRUS Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per s |
|
| February 10, 2015 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 9, 2015 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EPIRUS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 29428P107 (CUSIP Number) January 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2015 |
SC 13D/A 1 a15-40231sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D [Rule 13d-101] (Amendment No. 1)* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) EPIRUS Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29428P10 |
|
| February 9, 2015 |
EX-1 2 camberepirus13gexh1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 9, 2015 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States S |
|
| February 6, 2015 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 30, 2015 |
EPIRUS Announces Proposed Public Offering of Common Stock Exhibit 99.1 EPIRUS Announces Proposed Public Offering of Common Stock BOSTON—(BUSINESS WIRE)—January 26, 2015—EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today that it has commenced an underwritten public offering of shares of its common stock. EPIRUS intends to grant the |
|
| January 30, 2015 |
EPIRUS Prices $48 Million Public Offering of Common Stock Exhibit 99.2 EPIRUS Prices $48 Million Public Offering of Common Stock BOSTON—(BUSINESS WIRE)—January 30, 2015—EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today the pricing of an underwritten public offering of 9.6 million shares of its common stock, offered at a price to t |
|
| January 30, 2015 |
424B5 1 a2222902z424b5.htm 424B5 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-183538 Registration No. 333-201760 PROSPECTUS SUPPLEMENT (To prospectus dated September 17, 2012) 9,600,000 Shares Common Stock We are offering 9,600,000 shares of our common stock. Our common stock is listed on |
|
| January 30, 2015 |
Exhibit 1.1 9,600,000 Shares EPIRUS BIOPHARMACEUTICALS, INC. Common Stock, Par Value $0.001 Per Share UNDERWRITING AGREEMENT January 29, 2015 Leerink Partners LLC 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: EPIRUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwr |
|
| January 30, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) (C |
|
| January 29, 2015 |
EPRS / EPIRUS Biopharmaceuticals, Inc. S-3MEF - - S-3MEF As filed with the Securities and Exchange Commission on January 29, 2015 Registration No. |
|
| January 26, 2015 |
8-K 1 a15-305138k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 21, 2015 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdi |
|
| January 26, 2015 |
Exhibit 99.2 RISK FACTORS Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to |
|
| January 26, 2015 |
SUBJECT TO COMPLETION, DATED JANUARY 26, 2015 Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 26, 2015 |
Exhibit 99.1 BUSINESS Overview We are a commercial-stage biopharmaceutical company focused on improving patient access to important biopharmaceuticals by developing, manufacturing, and commercializing biosimilar therapeutics, or biosimilars, in targeted geographies worldwide. We seek to build a sustainable, profitable biosimilar company with a pipeline of operationally synergistic monoclonal antib |
|
| January 26, 2015 |
EPIRUS BIOPHARMACEUTICALS, INC. SEVERANCE PLAN Exhibit 10.1 EPIRUS BIOPHARMACEUTICALS, INC. SEVERANCE PLAN SECTION 1. Purpose. The purpose of this Severance Plan (this “Plan”) is to encourage certain management-level employees of EPIRUS Biopharmaceuticals, Inc. (the “Company”) and its subsidiaries to remain in the employ of the Company and its subsidiaries by providing severance protections to such employees in the event their employment is te |
|
| December 5, 2014 |
8-K 1 a14-2570718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 5, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisd |
|
| November 10, 2014 |
10-Q 1 a14-21803110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014. Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 10, 2014 |
AMENDMENT No. 1 to RANBAXY — EPIRUS LICENSE AGREEMENT EX-10.1 2 a14-218031ex10d1.htm EX-10.1 Exhibit 10.1 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. AMENDMENT No. 1 to RANBAXY — EPIRUS LICENSE AGREEMENT This Amendment No. 1, dated as of 09 September, 2014 (the “Amendment Effective Date”), t |
|
| November 10, 2014 |
EPIRUS MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 8 a14-218031ex99d1.htm EX-99.1 Exhibit 99.1 EPIRUS MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion of our financial condition and results of operations in conjunction with “Selected historical consolidated financial information” and the financial statements and related notes, all included elsewhere in this joint |
|
| November 10, 2014 |
EX-10.4 3 a14-218031ex10d4.htm EX-10.4 Exhibit 10.4 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN EPIRUS SWITZERLAND GmbH AND LIVZON MABPHARM INC. 1. DEFINITIONS 1 2. LICENSES 7 2 |
|
| November 10, 2014 |
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update Exhibit 99.1 EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update BOSTON, MA — November 10, 2014 - EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) ( |
|
| November 10, 2014 |
ONE EXETER PLAZA BOSTON, MASSACHUSETTS (THE “BUILDING”) FIRST AMENDMENT MAY 15, 2014 EX-10.6 4 a14-218031ex10d6.htm EX-10.6 Exhibit 10.6 ONE EXETER PLAZA BOSTON, MASSACHUSETTS (THE “BUILDING”) FIRST AMENDMENT MAY 15, 2014 LANDLORD: CPT One Exeter Plaza, LLC, a Delaware limited liability company with a principal place of business c/o AEW Capital Management, L.P., Two Seaport Lane, World Trade Center East, Boston, MA 02210 TENANT: EPIRUS Biopharmaceuticals, Inc., a Delaware corporat |
|
| October 31, 2014 |
SECOND AMENDMENT TO THE REVENUE AND NEGOTIATION RIGHTS AGREEMENT Exhibit 10.1 EXECUTION DRAFT SECOND AMENDMENT TO THE REVENUE AND NEGOTIATION RIGHTS AGREEMENT By this private instrument, the Parties, EPIRUS SWITZERLAND GMBH, a corporation organized under the laws of Switzerland, with registered office at General-Guisan-Strasse 6, 6303 Zug Switzerland (hereinafter referred to as “EPIRUS”), and as a successor to FOURTEEN22, INC. (“FOURTEEN22”), represented herein |
|
| October 31, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a14-2341018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisd |
|
| October 3, 2014 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| October 3, 2014 |
8-K 1 a14-2182718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Juri |
|
| October 3, 2014 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2014 and is entered into by and between EPIRUS BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES TECHNOLOGY GROWTH |
|
| September 29, 2014 |
8-K 1 a14-2157118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Juri |
|
| September 29, 2014 |
Exhibit 99.1 EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China Partners to develop, manufacture and commercialize up to five biosimilars, including EPIRUS’ BOW015, for Asian markets BOSTON, September 25, 2014 - EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar |
|
| September 29, 2014 |
FIRST AMENDMENT TO THE REVENUE AND NEGOTIATION RIGHTS AGREEMENT Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT TO THE REVENUE AND NEGOTIATION RIGHTS AGREEMENT By this private instrument, the Parties, EPIRUS SWITZERLAND GMBH, a corporation organized under the laws of Switzerland, with registered office at General-Guisan-Strasse 6, 6303 Zug Switzerland (hereinafter referred to as “EPIRUS”), and as a successor to FOURTEEN22, INC. (“FOURTEEN22”), represented herei |
|
| September 23, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51171 04-3514457 (State or Other Jurisdiction of Incorporation) |
|
| September 23, 2014 |
Exhibit 99.1 EPIRUS Announces Positive 58 Week Follow Up Data for BOW015 for treatment of Rheumatoid Arthritis BOW015 demonstrates therapeutic equivalence to Remicade® and confirms the safety of switching from Remicade to BOW015 BOSTON, September 23, 2014 - EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commerc |
|
| September 15, 2014 |
Entry into a Material Definitive Agreement 8-K 1 d788753d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| August 29, 2014 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / 5AM VENTURES III, L.P. - SCHEDULE 13D Activist Investment SC 13D 1 v388032sc13d.htm SCHEDULE 13D CUSIP NO. 29428P107 13D Page 1 of 13 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* EPIRUS Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (T |
|
| August 11, 2014 |
EX-10.11 Exhibit 10.11 June 15th, 2012 Michael Wyand Dear Michael: I am pleased to offer you a position with Fourteen22, Inc., a Delaware corporation (the “Company”), as its SVP of Clinical & Regulatory, reporting to the office of the CEO of the Company and shall begin on June 15th, 2012. If you decide to join us, you will receive an annual salary of $280,000, which will be paid in accordance with |
|
| August 11, 2014 |
AMENDMENT NO. 1 AMENDED AND RESTATED 2004 INCENTIVE PLAN EX-99.2 5 d761619dex992.htm EX-99.2 Exhibit 99.2 AMENDMENT NO. 1 TO AMENDED AND RESTATED 2004 INCENTIVE PLAN The Amended and Restated 2004 Incentive Plan (the “Plan”) of Zalicus Inc., a Delaware corporation (the “Company”), is hereby amended by the Board of Directors and stockholders of the Company, as follows: 1. The first sentence of Section 4(a) of the Plan is hereby deleted in its entirety and |
|
| August 11, 2014 |
EX-4.3 Exhibit 4.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
EX-4.2 Exhibit 4.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.01 EPIRUS BIOPHARMACEUTIOALSTM COMMON STOCK THIS CERTIFICATE IS TRANSFERABLE IN CANTON, MA, JERSEY CITY, NJ AND COLLEGE STATION, TX EPIRUS BIOPHARMACEUTICALS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** |
|
| August 11, 2014 |
EX-10.10 Exhibit 10.10 April 23, 2014 Robert Ticktin Dear Robert: I am pleased to offer you a position with Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), as General Counsel. Your employment shall begin on April 28, 2014. If you decide to join us, you will receive an annual salary of $275,000, which will be paid in accordance with the Company’s normal payroll procedures a |
|
| August 11, 2014 |
EX-10.12 Exhibit 10.12 Amit Munshi Dear Amit; Thank you for your very important contributions to EPIRUS in 2013. Your new salary for 2014 is $450,000 effective as of April 16, 2014. Your new 2014 bonus eligibility is 50%. We look forward to your contributions in 2014 and value you as a member of the EPIRUS team. Sincerely, /s/ Thomas Shea Thomas Shea Chief Financial Officer |
|
| August 11, 2014 |
EX-10.9 Exhibit 10.9 April 29, 2013 Thomas Shea Dear Thomas: I am pleased to offer you a position with EPIRUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), as the Chief Financial Officer (CFO), reporting to Amit Munshi; President & CEO. Your employment shall begin on May 20th, 2013. If you decide to join us, you will receive an annual salary of $275,000, which will be paid in a |
|
| August 11, 2014 |
EX-10.7 Exhibit 10.7 May 17, 2012 Amit Munshi Dear Amit: I am pleased to offer you a position with Fourteen22, Inc., a Delaware corporation (the “Company”), as its Chief Executive Officer, reporting to the Board of Directors of the Company. If you accept this offer, the Board of Directors will also appoint you as a Director of the Company and its President to serve during the period that you are t |
|
| August 11, 2014 |
SECOND DEFENITIVE LICENSE AGREEMENT EX-10.5 Exhibit 10.5 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. SECOND DEFENITIVE LICENSE AGREEMENT This SECOND DEFENITIVE LICENSE AGREEMENT (the “Agreement”) is made as of October 1st, 2013 (the “Effective Date”) by and between Epirus B |
|
| August 11, 2014 |
EX-10.4 Exhibit 10.4 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. EXECUTION VERSION 10/04/13 LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is made as of 10th of April (the “Effective Date”) by and between Epirus Biopharmaceuti |
|
| August 11, 2014 |
REVENUE AND NEGOTIATION RIGHTS AGREEMENT EX-10.3 Exhibit 10.3 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. REVENUE AND NEGOTIATION RIGHTS AGREEMENT This Revenue and Negotiation Rights Agreement (the “Agreement”), dated as of December 31, 2010 (the “Effective Date”), is entered in |
|
| August 11, 2014 |
EX-4.5 Exhibit 4.5 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
EX-10.16 Exhibit 10.16 LEASE AGREEMENT ONE EXETER PLAZA 699 BOYLSTON ST., BOSTON, MASSACHUSETTS L E A S E FROM CPT ONE EXETER PLAZA, LLC, A DELAWARE LIMITED LIABILITY COMPANY TO EPIRUS BIOPHARMACEUTICALS, INC. DATE: MARCH 8, 2013 TABLE OF CONTENTS ARTICLE 1 BASIC LEASE PROVISIONS 1 ARTICLE 2 PREMISES 4 ARTICLE 3 LEASE TERM AND EXTENSION OPTIONS 5 ARTICLE 4 LANDLORD’S WORK 6 ARTICLE 5 USE OF PREMIS |
|
| August 11, 2014 |
GPEx® CELL LINE SALE AGREEMENT EX-10.2 Exhibit 10.2 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. GPEx® CELL LINE SALE AGREEMENT This GPEx® Cell Line Sale Agreement (“Agreement”) is made and is effective as of this 1st day of January, 2009 (the “Effective Date”), by and |
|
| August 11, 2014 |
EX-10.8 Exhibit 10.8 February 4, 2014 Mr. Kim A. Seth By: Email Dear Kim I am pleased to offer you a position with Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), as the Senior Vice President & Chief Business Officer. Your employment shall begin on February 10, 2014 If you decide to join us, you will receive an annual salary of $280,000, which will be paid in accordance wi |
|
| August 11, 2014 |
EX-4.4 Exhibit 4.4 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
EX-4.6 Exhibit 4.6 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2014 |
EX-10.13 Exhibit 10.13 Kim Seth Dear Kim; Your new salary for 2014 is $300,000 effective as of April 16, 2014. Your new 2014 bonus eligibility is 35%. We look forward to your contributions in 2014 and value you as a member of the EPIRUS team. Sincerely, /s/ Amit Munshi Amit Munshi Chief Executive Officer |
|
| August 11, 2014 |
EX-4.7 Exhibit 4.7 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEM |
|
| August 11, 2014 |
EX-10.14 Exhibit 10.14 Tom Shea Dear Tom; Thank you for your very important contributions to EPIRUS in 2013. Your new salary for 2014 is $300,000 effective as of April 16, 2014. Your new 2014 bonus eligibility is 35%. We look forward to your contributions in 2014 and value you as a member of the EPIRUS team. Sincerely, /s/ Amit Munshi Amit Munshi Chief Executive Officer |
|
| August 11, 2014 |
EX-10.15 Exhibit 10.15 Michael Wyand Dear Michael; Thank you for your very important contributions to EPIRUS in 2013. Your new salary for 2014 is $300,000 effective as of April 16, 2014. Your new 2014 bonus eligibility is 35%. We look forward to your contributions in 2014 and value you as a member of the EPIRUS team. Sincerely, /s/ Amit Munshi Amit Munshi Chief Executive Officer |
|
| August 11, 2014 |
EX-10.6 Exhibit 10.6 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of 3rd January 2014 (the “Effective Date”) between Epirus Switzerland GmbH, a Swiss co |
|
| August 11, 2014 |
EPRS / EPIRUS Biopharmaceuticals, Inc. S-8 - - S-8 S-8 1 d761619ds8.htm S-8 Registration No. 333- As filed with the Securities and Exchange Commission on August 11, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3514457 (State or Other Jurisdiction of Incor |
|
| August 5, 2014 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / Livzon MABPharm Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) Under the Securities Exchange Act of 1934 Epirus Biopharmaceuticals, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 29428P 107 (CUSIP Number) July 15, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| July 25, 2014 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / TPG Group Holdings (SBS) Advisors, Inc. Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240. |
|
| July 25, 2014 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D Exhibit I AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. |
|
| July 25, 2014 |
EPRS / EPIRUS Biopharmaceuticals, Inc. / MONTREUX EQUITY PARTNERS IV LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* EPIRUS Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29428P107 (CUSIP Number) Daniel K. Turner, III One Ferry Building, Suite 255, San Francisco, CA 94111. (650) 234-1200 (Name, Address a |
|
| July 18, 2014 |
EX-10.2 Exhibit 10.2 May 27, 2014 Mark Corrigan Dear Mark, We are very pleased, in connection with the merger between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”) to offer you the position as Chairman of the Company’s Board of Directors (the “Board”). Your appointment is based on the following terms and conditions: Effective Date: Your |
|
| July 18, 2014 |
EX-3.01 Exhibit 3.01 AMENDED AND RESTATED BY-LAWS OF EPIRUS BIOPHARMACEUTICALS, INC. ARTICLE 1 - OFFICES 1 1.1 REGISTERED OFFICES 1 1.2 OTHER OFFICES 1 1.3 BOOKS 1 ARTICLE 2 - STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF MEETINGS 1 2.5 VOTING LIST 2 2.6 QUORUM 2 2.7 ADJOURNMENTS 2 2.8 VOTING AND PROXIES 2 2.9 PROXY REPRESENTATION 2 2.10 ACTION AT |
|
| July 18, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514 |
|
| July 18, 2014 |
EX-10.4 5 d757967dex104.htm EX-10.4 Exhibit 10.4 July 1, 2014 Julie McHugh Dear Julie, We are very pleased to name you as one of our director designees in connection with the merger between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”). Your appointment to become a member of the Company’s Board of Directors (the “Board”) is based on the |
|
| July 18, 2014 |
EPIRUS Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy EX-10.5 Exhibit 10.5 EPIRUS Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy Effective as of July 15, 2014 (the “Effective Date”), each member of the Board of Directors (the “Board”) who is not also serving as an employee of EPIRUS Biopharmaceuticals (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in th |
|
| July 18, 2014 |
EX-10.3 Exhibit 10.3 May 22, 2014 Bill Hunter Dear Bill, We are very pleased to name you as one of our director designees in connection with the merger between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”). Your appointment to become a member of the Company’s Board of Directors of the (the “Board”) is based on the following terms and co |
|
| July 15, 2014 |
8-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 15, 2014 |
EX-99.1 EXHIBIT 99.1 EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS) • 1:10 Reverse Stock Split will be effective before trading opens on July 16 • EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotia |
|
| July 15, 2014 |
CERTIFICATE OF AMENDMENT SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ZALICUS INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZALICUS INC. Zalicus Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is Zalicus Inc. The date of the filing of the Corporation’s original |
|
| July 15, 2014 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EPIRUS BIOPHARMACEUTICALS, INC. EPIRUS Biopharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is EPIRUS Biopharmaceuticals, |
|
| July 15, 2014 |
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of EX-99.2 EXHIBIT 99.2 Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors BOSTON, July 15, 2014 - EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, a |
|
| July 2, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission Fil |
|
| July 2, 2014 |
Termination of a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission Fil |
|
| June 27, 2014 |
SC 14F1 1 d750806dsc14f1.htm SC 14F1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14f-1 INFORMATION STATEMENT PURSUANT TO SECTION 14f OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER ZALICUS INC. (Exact name of registrant as specified in its charter) Delaware 000-51171 04-3514457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 25, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission Fil |
|
| June 25, 2014 |
ZALICUS AND EPIRUS AGREE ZALICUS STOCKHOLDERS TO OWN 19% OF COMBINED COMPANY POST-MERGER EX-99.1 Exhibit 99.1 ZALICUS AND EPIRUS AGREE ZALICUS STOCKHOLDERS TO OWN 19% OF COMBINED COMPANY POST-MERGER BOSTON, June 25, 2014 - Zalicus Inc. (Nasdaq Capital Market: ZLCS) (“Zalicus”), and Epirus Biopharmaceuticals, Inc. (“Epirus”) agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the |
|
| June 25, 2014 |
ZALICUS AND EPIRUS AGREE ZALICUS STOCKHOLDERS TO OWN 19% OF COMBINED COMPANY POST-MERGER EX-99.1 Exhibit 99.1 ZALICUS AND EPIRUS AGREE ZALICUS STOCKHOLDERS TO OWN 19% OF COMBINED COMPANY POST-MERGER BOSTON, June 25, 2014 - Zalicus Inc. (Nasdaq Capital Market: ZLCS) (“Zalicus”), and Epirus Biopharmaceuticals, Inc. (“Epirus”) agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the |
|
| June 25, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission Fil |
|
| June 18, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission Fil |
|
| June 18, 2014 |
EX-10.1 Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT THIS LICENSE AGREEMENT hereinafter (“AGREEMENT”) is made and entered into as of June 17, 2014 (hereinafter the “EFFECTIVE DATE”) by and between Zalicus Pharmaceuticals Ltd., c/o Zalicus Inc., with its principal place of business located at 245 First St. Third Floor, Cambridge, MA 02142 (hereinafter referred to as “ZALICUS” or “LICENSOR”), and AnaBio |
|
| June 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) (I |
|
| June 18, 2014 |
EX-99.1 Exhibit 99.1 Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 ZALICUS LICENSES SODIUM CHANNEL PAIN MODULATION PROGRAM Exclusive Rights Licensed to AnaBios Corporation in Exchange for more than $17 Millio |
|
| June 18, 2014 |
EX-10.1 2 d745020dex101.htm EX-10.1 Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT THIS LICENSE AGREEMENT hereinafter (“AGREEMENT”) is made and entered into as of June 17, 2014 (hereinafter the “EFFECTIVE DATE”) by and between Zalicus Pharmaceuticals Ltd., c/o Zalicus Inc., with its principal place of business located at 245 First St. Third Floor, Cambridge, MA 02142 (hereinafter referred to as “ZALICUS |
|
| June 18, 2014 |
EX-99.1 Exhibit 99.1 Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 ZALICUS LICENSES SODIUM CHANNEL PAIN MODULATION PROGRAM Exclusive Rights Licensed to AnaBios Corporation in Exchange for more than $17 Millio |
|
| June 6, 2014 |
UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS On June 2, 2014, Zalicus Inc. (“Zalicus” or the “Company”) completed the sale of its combination High Throughput Screening platform (the “cHTS Business”) and certain assets and liabilities related to the cHTS Business to Horizon Discovery Limited, an English private limited company, and Horizon Discovery Inc., a privately held |
|
| June 6, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File |
|
| June 6, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File |
|
| June 6, 2014 |
245 First Street, Third Floor Cambridge, Massachusetts 02142 424B3 1 d712283d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-195818 245 First Street, Third Floor Cambridge, Massachusetts 02142 June 6, 2014 Dear Stockholder: You are cordially invited to attend the 2014 Annual Meeting of Stockholders (the “Annual Meeting”) of Zalicus Inc. (“Zalicus” or the “Company”) to be held on July 15, 2014, at 9:00 a.m. local time, |
|
| June 6, 2014 |
UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS On June 2, 2014, Zalicus Inc. (“Zalicus” or the “Company”) completed the sale of its combination High Throughput Screening platform (the “cHTS Business”) and certain assets and liabilities related to the cHTS Business to Horizon Discovery Limited, an English private limited company, and Horizon Discovery Inc., a privately held |
|
| June 5, 2014 |
CORRESP 1 filename1.htm June 5, 2014 VIA EDGAR TRANSMISSION AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Jeffrey P. Riedler, Assistant Director Re: Zalicus Inc. Registration Statement on Form S-4 Filed May 8, 2014 File No. 333-195818 Dear Mr. Riedler: Pursuant to Rule 461 of the Securities Act of |
|
| June 4, 2014 |
THIS SPECIAL MEETING PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. EX-99.3 7 d712283dex993.htm EX-99.3 EXHIBIT 99.3 EPIRUS BIOPHARMACEUTICALS, INC. ATTN: EDWARD SCOTT 699 BOYLSTON ST. 11th FLOOR BOSTON, MA 02116 VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to EPIRUS Biopharmaceuticals, Inc., Attn: Edward Scott, 699 Boylston St. 11th Floor, Boston, MA 02116. TO VOTE, MARK BLOCKS BELOW IN |
|
| June 4, 2014 |
EX-99.2 6 d712283dex992.htm EX-99.2 EXHIBIT 99.2 FORM OF PROXY ZALICUS INC. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS 2014 Annual Meeting of Stockholders To Be Held On July 15, 2014 at 9:00 a.m., local time The undersigned stockholder of Zalicus Inc. (the “Company”) hereby acknowledges receipt of the Notice of 2014 Annual Meeting of Stockholders and the Joint Proxy Statement/Pros |
|
| June 4, 2014 |
S-4/A 1 d712283ds4a.htm AMENDMENT NO. 1 TO FORM S-4 Table of Contents As filed with the Securities and Exchange Commission on June 4, 2014 Registration No. 333-195818 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZALICUS INC. (Exact name of registrant as specified in its charter) Delaware 2 |
|
| June 4, 2014 |
CORRESP June 4, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 2, 2014 |
425 Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 ZALICUS ANNOUNCES CLOSING OF cHTS SERVICE BUSINESS SALE TO HORIZON DISCOVERY GROUP Combination High Throughput Screening Platform and Related Assets Sold for |
|
| May 22, 2014 |
425 1 d732432d425.htm 425 Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 ZALICUS UPDATES PROGRESS ON Z944 CLINICAL DEVELOPMENT Modified-release Formulation Selected for Clinical Advancement Translational Pharma |
|
| May 21, 2014 |
425 1 d729702d425.htm 425 Non-Confidential Investor Presentation Epirus–Zalicus Transaction & Epirus Corporate Overview Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 Non-Confidential Forward Looking Statement |
|
| May 15, 2014 |
Exhibit 99.1 ZALICUS TO SELL cHTS SERVICE BUSINESS TO HORIZON DISCOVERY GROUP Combination High Throughput Screening Platform and Related Assets Sold for $8 Million CAMBRIDGE, Mass. – May 15, 2014 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has entered into an agreeme |
|
| May 15, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) |
|
| May 15, 2014 |
EX-2.1 Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT BY AND AMONG HORIZON DISCOVERY LIMITED, HORIZON DISCOVERY INC., AND ZALICUS INC. Dated as of May 14, 2014 TABLE OF CONTENTS Page Section 1 - Purchase and Sale of Assets 1 1.1 Sale of Assets 1 1.2 Excluded Assets 3 1.3 Assumption of Liabilities 4 1.4 Assignment of Contracts and Rights 6 1.5 Signing and Closing 7 1.6 Purchase Price 7 1.7 |
|
| May 15, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) |
|
| May 15, 2014 |
EX-2.1 Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT BY AND AMONG HORIZON DISCOVERY LIMITED, HORIZON DISCOVERY INC., AND ZALICUS INC. Dated as of May 14, 2014 TABLE OF CONTENTS Page Section 1 - Purchase and Sale of Assets 1 1.1 Sale of Assets 1 1.2 Excluded Assets 3 1.3 Assumption of Liabilities 4 1.4 Assignment of Contracts and Rights 6 1.5 Signing and Closing 7 1.6 Purchase Price 7 1.7 |
|
| May 15, 2014 |
EX-99.1 3 d726127dex991.htm EX-99.1 Exhibit 99.1 ZALICUS TO SELL cHTS SERVICE BUSINESS TO HORIZON DISCOVERY GROUP Combination High Throughput Screening Platform and Related Assets Sold for $8 Million CAMBRIDGE, Mass. – May 15, 2014 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced |
|
| May 12, 2014 |
425 1 d724836d425.htm 425 Filed by Zalicus Inc. Pursuant to Rule 425 under Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Zalicus Inc. Registration Statement File No.: 333-195818 May 12, 2014 We are working with Epirus Biopharmaceuticals, Inc. (Epirus) to advise them on a merger agreement with Zalicus Inc. (Nasdaq: |
|
| May 9, 2014 |
ZALICUS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2014 EX-99.1 Exhibit 99.1 ZALICUS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2014 CAMBRIDGE, Mass. – May 9, 2014 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the first quarter ended March 31, 2014. “This was a significant quarter for Zalicus as we announc |
|
| May 9, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File |
|
| May 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d705474d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014. Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 9, 2014 |
DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| May 8, 2014 |
CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR EX-99.6 Exhibit 99.6 CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR The undersigned hereby consents to be named in the Registration Statement on Form S-4 to which this Consent has been filed as an exhibit, or any amendment thereto, as a person who shall become a Director of Zalicus Inc., such appointment to become effective upon consummation of the merger, as described in the Registrat |
|
| May 8, 2014 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of May 7, 2014, by and between Zalicus Inc., a Delaware corporation (“Phoenix”), and Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not def |
|
| May 8, 2014 |
CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR Exhibit 99.7 CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR The undersigned hereby consents to be named in the Registration Statement on Form S-4 to which this Consent has been filed as an exhibit, or any amendment thereto, as a person who shall become a Director of Zalicus Inc., such appointment to become effective upon consummation of the merger, as described in the Registration Stat |
|
| May 8, 2014 |
THIS SPECIAL MEETING PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. EX-99.3 8 d712283dex993.htm EX-99.3 EXHIBIT 99.3 EPIRUS BIOPHARMACEUTICALS, INC. ATTN: EDWARD SCOTT 699 BOYLSTON ST. 11th FLOOR BOSTON, MA 02116 VOTE BY INTERNET - [www.proxyvote.com] Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before [special meeting date]. Have your proxy card in hand when you access th |
|
| May 8, 2014 |
EPIRUS BIOPHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT EX-10.6 3 d712283dex106.htm EX-10.6 EXHIBIT 10.6 EPIRUS BIOPHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2011 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: «Name» Address: «Address» «CityStateZip |
|
| May 8, 2014 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION EX-10.1 2 d722832dex101.htm EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of May 7, 2014, by and between Zalicus Inc., a Delaware corporation (“Phoenix”), and Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”). Capita |
|
| May 8, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d722832d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514 |
|
| May 8, 2014 |
FOURTEEN22, INC. 2011 EQUITY INCENTIVE PLAN EX-10.5 EXHIBIT 10.5 FOURTEEN22, INC. 2011 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opti |
|
| May 8, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File |
|
| May 8, 2014 |
EX-99.2 EXHIBIT 99.2 FORM OF PROXY ZALICUS INC. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS 2014 Annual Meeting of Stockholders To Be Held On , 2014 at a.m., local time The undersigned stockholder of Zalicus Inc. (the “Company”) hereby acknowledges receipt of the Notice of 2014 Annual Meeting of Stockholders and the Joint Proxy Statement/Prospectus, each dated , 2014, and hereby ap |
|
| May 8, 2014 |
CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR EX-99.8 Exhibit 99.8 CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR The undersigned hereby consents to be named in the Registration Statement on Form S-4 to which this Consent has been filed as an exhibit, or any amendment thereto, as a person who shall become a Director of Zalicus Inc., such appointment to become effective upon consummation of the merger, as described in the Registrat |
|
| May 8, 2014 |
S-4 1 d712283ds4.htm FORM S-4 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZALICUS INC. (Exact name of registrant as specified in its charter) Delaware 2834 04-3514457 (State or other jurisdiction of |
|
| May 8, 2014 |
CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR EX-99.5 Exhibit 99.5 CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR The undersigned hereby consents to be named in the Registration Statement on Form S-4 to which this Consent has been filed as an exhibit, or any amendment thereto, as a person who shall become a Director of Zalicus Inc., such appointment to become effective upon consummation of the merger, as described in the Registrat |
|
| May 8, 2014 |
CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR EX-99.4 9 d712283dex994.htm EX-99.4 Exhibit 99.4 CONSENT TO BE NAMED AS A PERSON ABOUT TO BECOME A DIRECTOR The undersigned hereby consents to be named in the Registration Statement on Form S-4 to which this Consent has been filed as an exhibit, or any amendment thereto, as a person who shall become a Director of Zalicus Inc., such appointment to become effective upon consummation of the merger, a |
|
| April 30, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013. Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commiss |
|
| April 16, 2014 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ZALICUS INC., a Delaware corporation; BRUNNING, INC., a Delaware corporation; and EPIRUS BIOPHARMACEUTICALS, INC., a Delaware corporation Dated as of April 15, 2014 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 2 1.1 Structure of the Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Certif |
|
| April 16, 2014 |
EX-10.1 Exhibit 10.1 VOTING AGREEMENT THIS VOTING AGREEMENT (“Agreement”), dated as of April 15, 2014, is made by and among Zalicus Inc., a Delaware corporation (“Zalicus”), Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Zalicus. WHEREAS, Zalicus, BRunning, Inc., a Delaware corporation |
|
| April 16, 2014 |
Rule 425 Zalicus & Epirus Investor Call April 16, 2014 8:30AM Filed by Zalicus Inc. |
|
| April 16, 2014 |
EX-10.1 Exhibit 10.1 VOTING AGREEMENT THIS VOTING AGREEMENT (“Agreement”), dated as of April 15, 2014, is made by and among Zalicus Inc., a Delaware corporation (“Zalicus”), Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Zalicus. WHEREAS, Zalicus, BRunning, Inc., a Delaware corporation |
|
| April 16, 2014 |
EX-10.2 Exhibit 10.2 VOTING AGREEMENT THIS VOTING AGREEMENT (“Agreement”), dated as of April 15, 2014, is made by and among Zalicus Inc., a Delaware corporation (“Phoenix”), Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Phoenix, BRunning, Inc., a Delaware corpora |
|
| April 16, 2014 |
EX-99.1 5 d711860dex991.htm EX-99.1 Exhibit 99.1 Press Release Zalicus and Epirus Announce Merger Agreement • Merger will Create a Publicly Traded, Global Biosimilar Enterprise Focused on Improving Patient Access to Important Medicines • Epirus Closes $36 Million Series B Financing Round • Management to Hold Conference Call at 8:30 A.M. EDT BOSTON—(BUSINESS WIRE)—Apr. 16, 2014—Zalicus Inc. (Nasdaq |
|
| April 16, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No |
|
| April 16, 2014 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ZALICUS INC., a Delaware corporation; BRUNNING, INC., a Delaware corporation; and EPIRUS BIOPHARMACEUTICALS, INC., a Delaware corporation Dated as of April 15, 2014 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 2 1.1 Structure of the Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Certif |
|
| April 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) ( |
|
| April 16, 2014 |
EX-10.2 Exhibit 10.2 VOTING AGREEMENT THIS VOTING AGREEMENT (“Agreement”), dated as of April 15, 2014, is made by and among Zalicus Inc., a Delaware corporation (“Phoenix”), Epirus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Phoenix, BRunning, Inc., a Delaware corpora |
|
| April 16, 2014 |
EX-99.1 Exhibit 99.1 Press Release Zalicus and Epirus Announce Merger Agreement • Merger will Create a Publicly Traded, Global Biosimilar Enterprise Focused on Improving Patient Access to Important Medicines • Epirus Closes $36 Million Series B Financing Round • Management to Hold Conference Call at 8:30 A.M. EDT BOSTON—(BUSINESS WIRE)—Apr. 16, 2014—Zalicus Inc. (Nasdaq Capital Market: ZLCS) (Zali |
|
| April 1, 2014 |
EX-99.1 Exhibit 99.1 ZALICUS to Present at AACR 2014 Annual Meeting Zalicus and Collaborators Eisai and Sanofi Leverage Combination High-Throughput Screening Platform to Evaluate Combination Drug Synergies CAMBRIDGE, Mass. – April 1, 2014 – Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today ann |
|
| April 1, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) (I |
|
| March 14, 2014 |
EX-21.1 Exhibit 21.1 Subsidiaries of Zalicus Inc. Zalicus Pharmaceuticals Ltd.—formed in British Columbia |
|
| March 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2014 |
ZALICUS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR-END 2013 DC14236.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR-END 2013 Provides Update on Operations CAMBRIDGE, Mass. – March 13, 2014 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today |
|
| March 13, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rrd405380.htm ZALICUS FORM 8-K AND PRESS RELEASE EXHIBIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction |
|
| February 7, 2014 |
8-K 1 rrd401826.htm ZALICUS FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-5 |
|
| February 3, 2014 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2014 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commis |
|
| February 3, 2014 |
DC14138.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ROYALTY PURCHASE AGREEMENT BY AND BETWEEN MALLINCKRODT MEDICAL IMAGING - IRELAND AND ZALICUS PHARMACEUTICALS LTD. DATED AS OF JANUARY 31, 2014 1 THIS ROYALTY PURCHASE AGREEMENT dated as of January 31, 2014 (“Agreement”), is made by and between ZALICUS PHARMACEUTICALS LTD., formerly known as Neuromed Phar |
|
| November 12, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 rrd394994.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 |
|
| November 12, 2013 |
-Company to Discontinue Z160 Clinical Development- DC13961.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS REPORTS RESULTS FROM PHASE 2 CLINICAL TRIALS OF Z160 IN CHRONIC NEUROPATHIC PAIN -Company to Discontinue Z160 Clinical Development- CAMBRIDGE, Mass. – November 11, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments f |
|
| November 4, 2013 |
ZALICUS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER 2013 DC13892.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER 2013 CAMBRIDGE, Mass. – November 4, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the third |
|
| November 4, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rrd394165.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 ( |
|
| November 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013. Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-51 |
|
| November 1, 2013 |
DC13890.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS ANNOUNCES POSITIVE RESULTS OF Z944 PHASE 1B CLINICAL STUDY IN PAIN Efficacy Signals in Inflammatory and Neuropathic Pain Observed Second U.S. Patent Issues for Z944 Providing Exclusivity to 2029 CAMBRIDGE, Mass. – November 1, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmac |
|
| November 1, 2013 |
Financial Statements and Exhibits, Other Events - UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commis |
|
| October 15, 2013 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commis |
|
| October 15, 2013 |
ZALICUS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS DC13849.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS CAMBRIDGE, Mass. – October 15, 2013 – Zalicus Inc. (the “Company”) today announced that it has received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq Mark |
|
| October 2, 2013 |
CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZALICUS INC. DC13802.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZALICUS INC. Zalicus Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corp |
|
| October 2, 2013 |
ZALICUS ANNOUNCES 1-FOR-6 REVERSE STOCK SPLIT DC13795.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS ANNOUNCES 1-FOR-6 REVERSE STOCK SPLIT CAMBRIDGE, Mass. – October 2, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of De |
|
| October 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Commission File No.) |
|
| September 27, 2013 |
ZALICUS’ Z160 RECEIVES ORPHAN DRUG DESIGNATION FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA DC13788.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS’ Z160 RECEIVES ORPHAN DRUG DESIGNATION FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA CAMBRIDGE, Mass. – September 27, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announce |
|
| September 27, 2013 |
Financial Statements and Exhibits, Other Events - UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 (Comm |
|
| September 9, 2013 |
Experimental Clinical Study Expected to Complete During the Fourth Quarter 2013 DC13728.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing ZALICUS ZALICUS INITIATES PHASE 1b CLINICAL STUDY OF Z944, ITS NOVEL, ORAL, T-TYPE CALCIUM CHANNEL BLOCKER, FOR THE TREATMENT OF PAIN Experimental Clinical Study Expected to Complete During the Fourth Quarter 2013 CAMBRIDGE, Mass. – September 9, 2013 – Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biophar |
|
| September 9, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 rrd389911.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 |
|
| September 3, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 rrd389535.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2013 ZALICUS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51171 04-3514457 |
